I1F-MC-RHCG - ClinicalTrials.gov - NCT04527380
I1F-MC-RHCG - ClinicalTrials.gov - NCT04527380
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have active juvenile idiopathic arthritis (categories of enthesitis related arthritis or juvenile psoriatic arthritis)
Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years for participants with juvenile psoriatic arthritis and starting at 6 years for participants with enthesitis related arthritis
Participants must have all immunizations up-to-date in agreement with current immunization guidelines, in the opinion of the investigator
Participants must NOT
Participants must not have active or history of inflammatory bowel disease
Participants must not have active uveitis
Participants must not have active or latent tuberculosis
Participants must not have an active infection
Participants must not have concurrent use of biologic agents for the treatment of the juvenile idiopathic arthritis
Trial Summary
Conditions the trial is for
Enthesitis-Related Arthritis , Juvenile Psoriatic Arthritis
What the trial is testing?
Ixekizumab, Adalimumab
Could I receive a Placebo?
no
Enrollment Goal
100
Trial Dates
January 2021 - February 2025
Trial Phase
3
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participants must have active juvenile idiopathic arthritis (categories of enthesitis related arthritis or juvenile psoriatic arthritis)
Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years for participants with juvenile psoriatic arthritis and starting at 6 years for participants with enthesitis related arthritis
Participants must have all immunizations up-to-date in agreement with current immunization guidelines, in the opinion of the investigator
Participants must NOT
Participants must not have active or history of inflammatory bowel disease
Participants must not have active uveitis
Participants must not have active or latent tuberculosis
Participants must not have an active infection
Participants must not have concurrent use of biologic agents for the treatment of the juvenile idiopathic arthritis
Trial Summary
Conditions the trial is for
Enthesitis-Related Arthritis , Juvenile Psoriatic Arthritis
What the trial is testing?
Ixekizumab, Adalimumab
Could I receive a Placebo?
no
Enrollment Goal
100
Trial Dates
January 2021 - February 2025
Trial Phase
3
Trial Locations
Hide locations not currently recruiting